Available from stock

2-Chloro-2′-deoxyadenosine

SKU: C0805

Category: API's & Intermediates

Synonyms: CdA, Cladribine, 2-Chlorodeoxyadenosine, 2-Chloro-2?-deoxy-?-adenosine, NSC 105014-F, RWJ 26251; 4291-63-8
CAS-Number: C₁₀H₁₂ClN₅O₃
Molecular Formula: 285.69
Molecular Weight

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Appearance: White to off-white powder
Identity: 1H-NMR
Loss on Drying: ≤0.5%

Properties

Solvents: Soluble in DMSO (10mg/ml) or DMF (10mg/ml).
Melting Point: 228 - 230° C

Shipping: AMBIENT
Short Term Storage: RT
Long Term Storage: +4°C
Handling Advice: Protect from light and moisture.
Use / Stability: Stable for at least 2 years after receipt when stored at +4°C.

Hazard statements: H301,H341,H361fd,H372
Precautionary statements: P202 - P260 - P264 - P280 - P301 + P310 - P405
GHS Symbol: GHS06+GHS08
Signal word: Danger
RIDADR: UN2811
Transportation: Packing Group III

Description: 2-Chloro-2′-deoxyadenosine is a synthetic anticancer purine nucleoside analog commonly used in biochemical and cellular research to study nucleoside metabolism, DNA synthesis, and apoptosis pathways. Due to its resistance to adenosine deaminase–mediated degradation, this compound exhibits enhanced stability in biological systems, making it a valuable tool for mechanistic studies involving DNA replication and repair. Cladribine is cytotoxic to resting or proliferating lymphocytes. It inhibits RNA synthesis and induces DNA strand breaks in resting human peripheral blood lymphocytes. Cladribine induces cell cycle arrest at the G1 phase and apoptosis in U266, RPMI-8226, and MM.1S multiple myeloma cells in a concentration-dependent manner. It reduces tumor growth in HT-29 colon cancer, RL lymphoma, and RPMI-8226 multiple myeloma mouse xenograft models.
Smiles: Nc1nc(Cl)nc2n(cnc12)[C@H]3C[C@H](O)[C@@H](CO)O3
InChi Key: PTOAARAWEBMLNO-KVQBGUIXSA-N
References: [1] D.A. Carson, et al.; Blood 62, 737 (1983) , [2] S. Seto, et al.; J. Clin. Invest. 75, 377 (1985) , [3] E. Beutler; Lancet 340, 952 (1992) (Review) , [4] A. Gorski, et al.; Immunopharmacol. 26, 197 (1993) , [5] S. Spurgeon, et al.; Expert Opin. Investig. Drugs 18, 1169 (2009) (Review) , [6] J. Ma, et al.; BMC Cancer 11, 255 (2011) , [7] T.P. Leist & R. Weissert; Clin. Neuropharmacol. 34, 28 (2011) (Review) , [8] R. Hermann, et al.; Clin. Pharmacokinet. 60, 1509 (2021) (Review) , [9] R. Hermann, et al.; Clin. Pharmacokinet. 61, 167 (2022) (Review)

2-Chloro-2′-deoxyadenosine is a synthetic anticancer purine nucleoside analog commonly used in biochemical and cellular research to study nucleoside metabolism, DNA synthesis, and apoptosis pathways. Due to its resistance to adenosine deaminase–mediated degradation, this compound exhibits enhanced stability in biological systems, making it a valuable tool for mechanistic studies involving DNA replication and repair. Cladribine is cytotoxic to resting or proliferating lymphocytes. It inhibits RNA synthesis and induces DNA strand breaks in resting human peripheral blood lymphocytes. Cladribine induces cell cycle arrest at the G1 phase and apoptosis in U266, RPMI-8226, and MM.1S multiple myeloma cells in a concentration-dependent manner. It reduces tumor growth in HT-29 colon cancer, RL lymphoma, and RPMI-8226 multiple myeloma mouse xenograft models.

SKU: C0805 Category: API's & Intermediates

Additional information

Additional information

Synonyms	CdA, Cladribine, 2-Chlorodeoxyadenosine, 2-Chloro-2?-deoxy-?-adenosine, NSC 105014-F, RWJ 26251
Purity	≥98% (HPLC)
Appearance	White to off-white powder
CAS-Number	4291-63-8
Molecular Formula	C10H12ClN5O3
Molecular Weight	285.69
Identity	1H-NMR
Solvents	Soluble in DMSO (10mg/ml) or DMF (10mg/ml).
Melting Point	228 – 230° C
Smiles	Nc1nc(Cl)nc2n(cnc12)[C@H]3C[C@H](O)[C@@H](CO)O3
InChi Key	PTOAARAWEBMLNO-KVQBGUIXSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at +4°C.
Hazard statements	H301,H341,H361fd,H372
Precautionary statements	P202 – P260 – P264 – P280 – P301 + P310 – P405
GHS Symbol	GHS06+GHS08
Signal word	Danger
RIDADR	UN2811
Transportation	Packing Group III
References	[1] D.A. Carson, et al.; Blood 62, 737 (1983), [2] S. Seto, et al.; J. Clin. Invest. 75, 377 (1985), [3] E. Beutler; Lancet 340, 952 (1992) (Review), [4] A. Gorski, et al.; Immunopharmacol. 26, 197 (1993), [5] S. Spurgeon, et al.; Expert Opin. Investig. Drugs 18, 1169 (2009) (Review), [6] J. Ma, et al.; BMC Cancer 11, 255 (2011), [7] T.P. Leist & R. Weissert; Clin. Neuropharmacol. 34, 28 (2011) (Review), [8] R. Hermann, et al.; Clin. Pharmacokinet. 60, 1509 (2021) (Review), [9] R. Hermann, et al.; Clin. Pharmacokinet. 61, 167 (2022) (Review)
Quantity	10 mg, 25 mg, Bulk
cdx-Loss on Drying	≤0.5%